iBET

What iBET does

iBET (Instituto de Biologia Experimental e Tecnológica) is a private non-profit Portuguese biotechnology research institute founded in 1989 and headquartered in Oeiras, Portugal, operating with 270 staff including 110+ PhD holders across 14 research teams. The organization specializes in bioprocess engineering for biopharmaceuticals, combining upstream and downstream technologies across cell therapy products (hPSC, MSC, CAR-T), gene therapy viral vectors (retrovirus, lentivirus, adenovirus, AAV), vaccine production (VLPs, vectored, live attenuated), advanced 3D human cell models for drug discovery, protein biophysics and structure-based drug design, and natural bioactives for the food/health sector. Its technical platform includes bioreactors from 80mL to 50L (glass, stainless steel, and disposable), a cGMP-certified Analytical Services Unit (GMP-certified by INFARMED and DGAV since 2013), and proprietary methods such as Extract2Chip for Surface Plasmon Resonance studies.

iBET's business model combines three revenue streams: (1) industry R&D contracts including long-term embedded satellite laboratory arrangements with Merck (since 2006), Bayer (since 2006), Novartis (since 2013), and Sanofi (since 2017), totaling 150+ industry R&D projects; (2) competitive public research funding from EU programs (Horizon Europe, H2020, EU4Health), Portuguese national sources (FCT, PRR), and international funders (Japanese GHIT Fund), supporting 200+ competitively funded projects; and (3) GMP-certified analytical services provided to pharmaceutical and biotech companies. The organization's go-to-market is enterprise field sales, with new business development supported by 400+ peer-reviewed publications, participation in major EU consortia (iNOVA4Health, LS4Future, BRAVŒ, ARDAT, EATRIS, European Vaccines Hub), and the 4.7M EUR iBETXplore internal innovation program. In 2025, iBET expanded its commercial footprint through the ViSync Technologies joint venture with Hovione targeting cell and gene therapy services.

The organization is governed by its own Executive Committee and Board of Directors with oversight from an International Scientific Advisory Board. A spin-off created in 2006 (GenIbet Biopharmaceuticals, focused on Phase I/II clinical trial manufacturing) was divested to Swedish CDMO Recipharm in 2022. iBET's recent capital investment in the 6,000 m² Biofarma building (inaugurated June 2023) and its 2025 strategic moves — including ViSync Technologies, European Vaccines Hub membership, ESG project kick-off, and Sustainability for Food & Health Division restructuring — indicate an organization scaling capacity and diversifying its vertical and geographic footprint while deepening its core biopharma research services offering.

Name

iBET

Legal name

Instituto de Biologia Experimental e Tecnológica – iBET

Website

https://ibet.pt

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

101–250 employees

Short description

iBET is a Portuguese private non-profit biotechnology research institute providing bioprocess R&D services, satellite laboratories, and cGMP analytical services to global biopharmaceutical and biotech companies, with expertise spanning cell therapies, gene therapy vectors, vaccines, and advanced 3D cell models.

Ownership category

akta.pro rank

Headquarters

HQ city

Oeiras

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Industry R&D Partnerships: Contract research services and collaborative R&D projects with biopharmaceutical companies including satellite laboratory arrangements with Merck, Novartis, Bayer, and Sanofi.
2. Public Research Funding: Competitive funding from EU programs (Horizon Europe, H2020, EU4Health), national funding (FCT, PRR), and international sources (GHIT Fund). Over 200 R&D projects with competitive funding.
3. GMP Analytical Services: The Analytical Services Unit (ASU) holds GMP certification from INFARMED and DGAV, providing analytical services for pharmaceutical and biotech companies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

iBET is a private non-profit research organization that provides contract R&D services to global biopharma and biotech partners. Its core offerings span bioprocess development and scale-up for cell therapies, gene therapy viral vectors, and vaccines, supported by cGMP-certified analytical services, protein biophysics and structure-based drug design, advanced 3D cell models, and multi-omics characterization. Services are delivered through embedded satellite laboratories with major pharma companies and bilateral collaborative R&D contracts.

Product overview

iBET (Instituto de Biologia Experimental e Tecnológica) is a private non-profit biotechnology research institute that provides research services to biopharma and biotech partners rather than a single software product. The portfolio consists of core research service areas (Bioengineering for Cell-based Therapies, Gene Therapy Products, Vaccines Bioprocess Engineering, Advanced Cell Models, Translational Immunology, Protein Biophysics, Microbiology, and Natural Bioactives) supported by technical units (Late-Stage R&D/Bioproduction, cGMP Analytical Services, Mass Spectrometry, Flow Cytometry, Data Analytics Center). iBET also operates satellite laboratories with major pharma partners (Bayer, Novartis, Sanofi, Merck), runs the iBETXplore internal innovation program, and coordinates the iNOVA4Health research unit. Services span from early R&D through scale-up to GMP production for biopharmaceuticals and advanced therapy medicinal products (ATMPs).

Differentiator

Problem solved

Functional benefit

Products and services

• Bioengineering for Cell-based Therapies

Quantifiable outcome

• 150+ industry R&D projects completed
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

20 partnerships are on record, tiered core and notable.

• European Vaccines Hub (EVH)coreStrategic or Co-development Partner · 1 March 2025iBET joined the flagship European Vaccines Hub for Pandemic Readiness in 2025, a new EU co-funded public-private partnership focused on developing vaccines of public health relevance.
• OneChain ImmunotherapeuticscoreStrategic or Co-development Partner · 1 April 2023European consortium led by OneChain Immunotherapeutics developing CAR T-cell based therapy against T-cell acute lymphoblastic leukaemia under EIC Transition Challenge (Grant Agreement nº 101113067). iBET playing key role in translating production process to industrial level.
• LS4Future (Life Sciences for a Healthy and Sustainable Future)coreStrategic or Co-development Partner · 1 January 2023Associate Laboratory funded by FCT with partner institutes ITQB NOVA, IGC, NOVA Medical School, and IPOLFG (Lisbon Oncology Hospital).
• EATRISnotableStrategic or Co-development Partner · 1 January 2023European Infrastructure for Translational Medicine - Non-profit European Research Infrastructure Consortium. iBET participates in this pan-European network for translational medicine.
• BRAVƎ ConsortiumcoreStrategic or Co-development Partner · 1 January 2022EU Horizon 2020 project developing scalable bioprocesses for hPSC-derived cardiac cells for BioVAD (Biological Ventricular Assisted Device). Consortium includes University of Navarra and University Medical Center Utrecht.
• ViSync TechnologiesnotableStrategic or Co-development Partner · 1 January 2022Jointly owned venture launched by iBET and Hovione (Associate Member) dedicated to addressing unmet technical needs of pharmaceutical companies in cell and gene therapy.
• ARDAT ConsortiumcoreStrategic or Co-development Partner · 1 January 2022EU-funded consortium of 34 international partners developing knowledge, tools and standards to accelerate ATMP development for rare diseases. iBET developing 3D innate immune-competent CNS models for gene therapy studies.
• ADDovenom ConsortiumnotableStrategic or Co-development Partner · 1 January 2020EU-FET funded project creating snakebite antivenom treatment using VLP-based ADDomers. iBET's role is to establish scalable, GMP-compliant platform for production.
• SanoficoreStrategic or Co-development Partner · 1 January 2017Sanofi Satellite Laboratory contract signed in 2017, marking iBET's fourth satellite laboratory with international biopharma companies. Advancing process understanding capabilities in biopharmaceuticals development platforms.
• Novartis Pharma AGcoreStrategic or Co-development Partner · 1 January 2013Third satellite laboratory launched at iBET in 2013 as a node of Novartis R&D, marking a long-term partnership both organizations consider successful in creating value together.
• iNOVA4Health R&D UnitcoreStrategic or Co-development Partner · 1 January 2013iNOVA4Health R&D Unit launched in 2013, funded by FCT and coordinated by iBET. Awarded Seal of Excellent by FCT in 2025. Focuses on advancing precision medicine.
• Merck Healthcare KGaAcoreStrategic or Co-development Partner · 1 January 2006Merck Satellite Laboratory established at iBET in 2006, providing seamless integration of structural studies, biochemical assays and molecular interaction approaches to support preclinical drug discovery programs for Merck Healthcare KGaA.
• Bayer AGcoreStrategic or Co-development Partner · 1 January 2006Bayer Pharma Laboratory established as a satellite laboratory at iBET for enhancing antibody discovery and pre-clinical profiling. Represents a node of Bayer R&D.
• ITQB NOVAcoreStrategic or Co-development PartnerLong-term institutional partner within the Oeiras Associate Laboratory status and LS4Future Associate Laboratory. Adjacent research institute sharing the iBET/ITQB building in Oeiras.
• GenIbet BiopharmaceuticalsnotableOthersSpin-off created by iBET in 2006 dedicated to producing biopharmaceuticals for phase I/II clinical trials. Acquired by Swedish CDMO Recipharm in 2022.
• HovionecoreStrategic or Co-development PartneriBET Associate Member and joint venture partner in ViSync Technologies, focused on cell and gene therapy solutions.
• Boehringer Ingelheim InternationalnotableStrategic or Co-development PartnerCollaboration developing human 3D hepatic models to explore liver innate immune response to rAAV gene therapy vectors, establishing Kupffer-like cell differentiation protocol.
• AbbVienotableStrategic or Co-development PartnerCollaboration resulting in patient-derived cancer ex vivo models and application to discovery and development of cancer immunotherapeutics (2017-2022). Included postdoctoral researcher, 3 PhD theses, 2 MSc theses.
• Merck Global HealthnotableStrategic or Co-development PartnerLong-term collaboration developing 3D models of hepatic Plasmodium infection for malaria drug discovery with iMM Lisbon. Results contributed to phase I clinical trial dosing.
• TEC4GREEN ConsortiumnotableStrategic or Co-development Partner18 national partners, 15.9M€ funding from PRR, aiming to equip agro-industrial sector for future challenges through biological products, digital farming, and circular economy.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Evotec SE: Hamburg-based contract research and discovery services organization with cell and gene therapy, biologics, and bioprocess capabilities serving global biopharma — directly comparable in mission, customer base, and service mix to iBET, though at significantly larger scale and as a publicly listed for-profit.
• Cell and Gene Therapy Catapult: UK-based non-profit innovation and technology organization focused on advancing cell and gene therapy development, providing R&D, bioprocess, and GMP manufacturing services to industry — closely mirrors iBET's mission, ATMP focus, and public-private funding model.
• Fraunhofer Institute (IMB / ITEM): German applied-research non-profit performing contract R&D in biotechnology, bioprocess, and pharma for industry and public funders — closely comparable institutional model, public-funding mix, and industry-partner engagement style to iBET.
• VTT Technical Research Centre of Finland: European non-profit applied research organization providing contract biotechnology, bioprocess, and industrial biotech R&D services to industry — structurally and operationally similar to iBET in mission, scale, and EU/industry funding mix.

Broad incumbents

• Lonza Group: Global CDMO providing mammalian cell culture, viral vector, and bioprocess development and manufacturing services for biopharmaceuticals — broader commercial-manufacturing scale, but directly competes with iBET for bioprocess development and ATMP process work.
• Catalent (Novo Holdings): Major global CDMO with cell and gene therapy, biologics, and vaccine capabilities including bioprocess development — comparable service offering to iBET but at commercial scale across multiple modalities.
• Charles River Laboratories: Large contract research organization with biopharma services spanning discovery, bioprocess, and safety assessment — overlaps with iBET's research-services model and large-pharma customer base, though significantly broader in scope and geographic reach.
• WuXi Biologics: Global CRO/CDMO providing biologics discovery, development, and manufacturing services — competes for outsourced bioprocess and cell line development work with iBET's biopharma customers, but at much larger scale and broader service portfolio.

Others

• Sartorius AG: Leading supplier of bioreactors, bioprocess equipment, and process solutions for the biopharmaceutical industry — adjacent ecosystem participant whose bioprocess tools and technologies enable much of the upstream/downstream work iBET performs.

Regional players

• National Research Council of Italy (CNR): Italy's largest public research organization conducting biotechnology, biomedical, and pharmaceutical R&D for industry and government — comparable institutional mission and contract-research function to iBET but operating at national scale within Italy rather than primarily Portugal-based engagements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/iBET_Portugal

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iBET